Prevalence and management of lower urinary tract symptoms in methamphetamine abusers

An under-recognized clinical identity

Kyo Chul Koo, Dong Hoon Lee, Jang Hwan Kim, KoonHo Rha, Byungha Chung, Sung Joon Hong, Sang Yol Mah

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Purpose We investigate the prevalence of lower urinary tract symptoms in a cohort of methamphetamine abusers, and assess the therapeutic efficacy of α-blockers and anticholinergics. Materials and Methods From May 2011 to March 2013, 78 male methamphetamine abusers diagnosed with methamphetamine addiction were identified at the National Forensic Hospital, Korea. The I-PSS (International Prostate Symptom Score) with consultation was used to investigate the prevalence of lower urinary tract symptoms, defined as total I-PSS 8 or greater and quality of life index score of 2 or greater. These values for methamphetamine abusers were compared to those of 71 age matched controls. α-Blockers and anticholinergics were administered to methamphetamine abusers with lower urinary tract symptoms according to predominant voiding and storage symptoms based on voiding-to-storage subscore ratios. For methamphetamine abusers with no response, defined as a reduction of 4 or less in total I-PSS, an alternative drug or combination was administered. Efficacy was assessed based on a 4-week interval. Results The median periods of methamphetamine abuse and abstinence were 18.1 years and 5.7 months, respectively. Methamphetamine abusers showed a higher prevalence of lower urinary tract symptoms compared to controls (77% vs 15%, p <0.001), with higher I-PSS and quality of life index score (13.3 vs 5.6 and 2.9 vs 0.9, respectively; p <0.001). Anticholinergics showed the greatest effect on I-PSS reduction with overall response rates for α-blockers, anticholinergics and combinations of 13%, 61% and 14%, respectively. Seven (12%) methamphetamine abusers did not respond to any therapy. Conclusions Lower urinary tract symptoms were highly prevalent among methamphetamine abusers. Our results imply that pathological dopaminergic mechanisms have a role in methamphetamine associated lower urinary tract symptoms. Moreover, first line anticholinergics and prompt combination with α-blockers conferred the most therapeutic benefit to nonresponders.

Original languageEnglish
Pages (from-to)722-726
Number of pages5
JournalJournal of Urology
Volume191
Issue number3
DOIs
Publication statusPublished - 2014 Mar 1

Fingerprint

Lower Urinary Tract Symptoms
Methamphetamine
Cholinergic Antagonists
Prostate
Quality of Life
Drug Combinations
Korea
Therapeutics
Referral and Consultation

All Science Journal Classification (ASJC) codes

  • Urology

Cite this

Koo, Kyo Chul ; Lee, Dong Hoon ; Kim, Jang Hwan ; Rha, KoonHo ; Chung, Byungha ; Hong, Sung Joon ; Mah, Sang Yol. / Prevalence and management of lower urinary tract symptoms in methamphetamine abusers : An under-recognized clinical identity. In: Journal of Urology. 2014 ; Vol. 191, No. 3. pp. 722-726.
@article{7df8a70e707e4753997c0202d76ce193,
title = "Prevalence and management of lower urinary tract symptoms in methamphetamine abusers: An under-recognized clinical identity",
abstract = "Purpose We investigate the prevalence of lower urinary tract symptoms in a cohort of methamphetamine abusers, and assess the therapeutic efficacy of α-blockers and anticholinergics. Materials and Methods From May 2011 to March 2013, 78 male methamphetamine abusers diagnosed with methamphetamine addiction were identified at the National Forensic Hospital, Korea. The I-PSS (International Prostate Symptom Score) with consultation was used to investigate the prevalence of lower urinary tract symptoms, defined as total I-PSS 8 or greater and quality of life index score of 2 or greater. These values for methamphetamine abusers were compared to those of 71 age matched controls. α-Blockers and anticholinergics were administered to methamphetamine abusers with lower urinary tract symptoms according to predominant voiding and storage symptoms based on voiding-to-storage subscore ratios. For methamphetamine abusers with no response, defined as a reduction of 4 or less in total I-PSS, an alternative drug or combination was administered. Efficacy was assessed based on a 4-week interval. Results The median periods of methamphetamine abuse and abstinence were 18.1 years and 5.7 months, respectively. Methamphetamine abusers showed a higher prevalence of lower urinary tract symptoms compared to controls (77{\%} vs 15{\%}, p <0.001), with higher I-PSS and quality of life index score (13.3 vs 5.6 and 2.9 vs 0.9, respectively; p <0.001). Anticholinergics showed the greatest effect on I-PSS reduction with overall response rates for α-blockers, anticholinergics and combinations of 13{\%}, 61{\%} and 14{\%}, respectively. Seven (12{\%}) methamphetamine abusers did not respond to any therapy. Conclusions Lower urinary tract symptoms were highly prevalent among methamphetamine abusers. Our results imply that pathological dopaminergic mechanisms have a role in methamphetamine associated lower urinary tract symptoms. Moreover, first line anticholinergics and prompt combination with α-blockers conferred the most therapeutic benefit to nonresponders.",
author = "Koo, {Kyo Chul} and Lee, {Dong Hoon} and Kim, {Jang Hwan} and KoonHo Rha and Byungha Chung and Hong, {Sung Joon} and Mah, {Sang Yol}",
year = "2014",
month = "3",
day = "1",
doi = "10.1016/j.juro.2013.08.020",
language = "English",
volume = "191",
pages = "722--726",
journal = "Journal of Urology",
issn = "0022-5347",
publisher = "Elsevier Inc.",
number = "3",

}

Prevalence and management of lower urinary tract symptoms in methamphetamine abusers : An under-recognized clinical identity. / Koo, Kyo Chul; Lee, Dong Hoon; Kim, Jang Hwan; Rha, KoonHo; Chung, Byungha; Hong, Sung Joon; Mah, Sang Yol.

In: Journal of Urology, Vol. 191, No. 3, 01.03.2014, p. 722-726.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Prevalence and management of lower urinary tract symptoms in methamphetamine abusers

T2 - An under-recognized clinical identity

AU - Koo, Kyo Chul

AU - Lee, Dong Hoon

AU - Kim, Jang Hwan

AU - Rha, KoonHo

AU - Chung, Byungha

AU - Hong, Sung Joon

AU - Mah, Sang Yol

PY - 2014/3/1

Y1 - 2014/3/1

N2 - Purpose We investigate the prevalence of lower urinary tract symptoms in a cohort of methamphetamine abusers, and assess the therapeutic efficacy of α-blockers and anticholinergics. Materials and Methods From May 2011 to March 2013, 78 male methamphetamine abusers diagnosed with methamphetamine addiction were identified at the National Forensic Hospital, Korea. The I-PSS (International Prostate Symptom Score) with consultation was used to investigate the prevalence of lower urinary tract symptoms, defined as total I-PSS 8 or greater and quality of life index score of 2 or greater. These values for methamphetamine abusers were compared to those of 71 age matched controls. α-Blockers and anticholinergics were administered to methamphetamine abusers with lower urinary tract symptoms according to predominant voiding and storage symptoms based on voiding-to-storage subscore ratios. For methamphetamine abusers with no response, defined as a reduction of 4 or less in total I-PSS, an alternative drug or combination was administered. Efficacy was assessed based on a 4-week interval. Results The median periods of methamphetamine abuse and abstinence were 18.1 years and 5.7 months, respectively. Methamphetamine abusers showed a higher prevalence of lower urinary tract symptoms compared to controls (77% vs 15%, p <0.001), with higher I-PSS and quality of life index score (13.3 vs 5.6 and 2.9 vs 0.9, respectively; p <0.001). Anticholinergics showed the greatest effect on I-PSS reduction with overall response rates for α-blockers, anticholinergics and combinations of 13%, 61% and 14%, respectively. Seven (12%) methamphetamine abusers did not respond to any therapy. Conclusions Lower urinary tract symptoms were highly prevalent among methamphetamine abusers. Our results imply that pathological dopaminergic mechanisms have a role in methamphetamine associated lower urinary tract symptoms. Moreover, first line anticholinergics and prompt combination with α-blockers conferred the most therapeutic benefit to nonresponders.

AB - Purpose We investigate the prevalence of lower urinary tract symptoms in a cohort of methamphetamine abusers, and assess the therapeutic efficacy of α-blockers and anticholinergics. Materials and Methods From May 2011 to March 2013, 78 male methamphetamine abusers diagnosed with methamphetamine addiction were identified at the National Forensic Hospital, Korea. The I-PSS (International Prostate Symptom Score) with consultation was used to investigate the prevalence of lower urinary tract symptoms, defined as total I-PSS 8 or greater and quality of life index score of 2 or greater. These values for methamphetamine abusers were compared to those of 71 age matched controls. α-Blockers and anticholinergics were administered to methamphetamine abusers with lower urinary tract symptoms according to predominant voiding and storage symptoms based on voiding-to-storage subscore ratios. For methamphetamine abusers with no response, defined as a reduction of 4 or less in total I-PSS, an alternative drug or combination was administered. Efficacy was assessed based on a 4-week interval. Results The median periods of methamphetamine abuse and abstinence were 18.1 years and 5.7 months, respectively. Methamphetamine abusers showed a higher prevalence of lower urinary tract symptoms compared to controls (77% vs 15%, p <0.001), with higher I-PSS and quality of life index score (13.3 vs 5.6 and 2.9 vs 0.9, respectively; p <0.001). Anticholinergics showed the greatest effect on I-PSS reduction with overall response rates for α-blockers, anticholinergics and combinations of 13%, 61% and 14%, respectively. Seven (12%) methamphetamine abusers did not respond to any therapy. Conclusions Lower urinary tract symptoms were highly prevalent among methamphetamine abusers. Our results imply that pathological dopaminergic mechanisms have a role in methamphetamine associated lower urinary tract symptoms. Moreover, first line anticholinergics and prompt combination with α-blockers conferred the most therapeutic benefit to nonresponders.

UR - http://www.scopus.com/inward/record.url?scp=84893830514&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84893830514&partnerID=8YFLogxK

U2 - 10.1016/j.juro.2013.08.020

DO - 10.1016/j.juro.2013.08.020

M3 - Article

VL - 191

SP - 722

EP - 726

JO - Journal of Urology

JF - Journal of Urology

SN - 0022-5347

IS - 3

ER -